FULC News and Press, Fulcrum Therapeutics Inc. From 03/28/24

CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today ...

2024-03-27 20:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-18 08:02:15 ET More on Fulcrum Therapeutics Fulcrum hits 52-week high as CEO buys shares Seeking Alpha’s Quant Rating on Fulcrum Therapeutics Historical earnings data for Fulcrum Therapeutics Financial information for Fulcrum Therapeutics ...

―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will cont...

2024-03-06 12:14:26 ET Fulcrum Therapeutics ( NASDAQ: FULC ) traded higher on Wednesday to reach a new 52-week high on above-average volumes after its newly appointed chief executive, Alex Sapir, purchased company shares for the first time.... Read the full article on Seeking ...

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is the focus of IBN's latest stock spotlight. The company's shares have moved 19.25% on the day to $13.07. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with g...

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today ...

― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral m uscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Restart of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) underway ― ...

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

2024-02-26 05:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...